{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:52:50Z","timestamp":1787169170222,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jfma.2025.09.014","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:18:24Z","timestamp":1757769504000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comparative analysis of persistence of advanced therapies among patients with inflammatory bowel disease in Taiwan"],"prefix":"10.1016","author":[{"given":"Horng-Yih","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-8565","authenticated-orcid":false,"given":"Ming-Wei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-1504","authenticated-orcid":false,"given":"Chien-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Tang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2004-1526","authenticated-orcid":false,"given":"Yu-Bin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-5371","authenticated-orcid":false,"given":"Puo-Hsien","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9573","key":"10.1016\/j.jfma.2025.09.014_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jfma.2025.09.014_bib2","doi-asserted-by":"crossref","first-page":"e974","DOI":"10.1016\/j.cgh.2020.10.008","article-title":"Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study","volume":"20","author":"Khoudari","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.09.014_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"10.1016\/j.jfma.2025.09.014_bib4","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.jfma.2025.09.014_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study","volume":"54","author":"Ko","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jfma.2025.09.014_bib6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","article-title":"Comparative efficacy of advanced therapies for achieving endoscopic outcomes in Crohn's disease: a systematic review and network meta-analysis","volume":"22","author":"Vuyyuru","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jfma.2025.09.014_bib7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jfma.2025.09.014_bib8","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10342","key":"10.1016\/j.jfma.2025.09.014_bib9","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jfma.2025.09.014_bib10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","article-title":"Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY)","volume":"161","author":"Peyrin-Biroulet","year":"2021","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.jfma.2025.09.014_bib11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.09.014_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.09.014_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jfma.2025.09.014_bib14","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/ibd\/izac269","article-title":"Real-world evidence of effectiveness and safety of vedolizumab for inflammatory bowel disease in Taiwan: a prospective Nationwide registry (violet) study","volume":"29","author":"Lin","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.jfma.2025.09.014_bib15","first-page":"CD012774","article-title":"Fecal transplantation for treatment of inflammatory bowel disease","volume":"4","author":"Imdad","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.jfma.2025.09.014_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.jfma.2025.09.014_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jfma.2025.09.014_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062397","article-title":"Comparison of the persistence of anti-TNF agents and ustekinumab in patients with Crohn's disease: a study based on the Korean National Database","volume":"12","author":"Seo","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jfma.2025.09.014_bib19","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2665-9913(23)00341-7","article-title":"Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials","volume":"6","author":"Brun","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"20","key":"10.1016\/j.jfma.2025.09.014_bib20","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625004966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625004966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T21:19:25Z","timestamp":1758662365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625004966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"alternative-id":["S0929664625004966"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.09.014","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative analysis of persistence of advanced therapies among patients with inflammatory bowel disease in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}